Skip to Main Content

Lloyd Damon


Advocate for personalized medicine

Dr. Lloyd Damon is a hematologist and researcher who specializes in blood cancers such as lymphomas and leukemias.

Damon studies new treatments for acute myeloid and acute lymphoblastic leukemias. In 1995, he was an early investigator of rituximab, the first monoclonal antibody approved to treat human cancer, specifically lymphoma. (Monoclonal antibodies are cancer-fighting molecules produced in the lab and then infused to work with the patient's immune system against cancer.) In 1998, Damon developed a high-dose regimen for mantle cell lymphoma involving autologous stem cell transplants – which use the patient's own stem cells. When studying cytarabine, an important leukemia drug, he discovered the risk factors for an uncommon toxic effect it can have on the brain and then developed a method for modifying the dose that reduces this side effect significantly.

Damon earned his medical degree at the University of Michigan. He completed an internal medicine residency and a fellowship in hematology and oncology at UCSF, where he joined the faculty in 1988. He is deputy chief of the Divisions of Hematology and Medical Oncology.

  • Education

    University of Michigan, 1982

  • Residencies

    UCSF, Internal Medicine, 1985

  • Fellowships

    UCSF, Hematology/Oncology, 1988

  • Board Certifications

    Hematology, American Board of Internal Medicine

    Medical Oncology, American Board of Internal Medicine

    Internal Medicine, American Board of Internal Medicine

  • Academic Title



All blood diseases – malignant or benign – are significant, and I take a personalized approach to every patient.

Where I see patients (1)

    My reviews


    Overall Experience
    273 Ratings
    Explained things in a way that was easy to understand
    272 Ratings
    Did the doctor pay attention to your concerns
    272 Ratings
    Gave easy to understand instructions about taking care of health problems or concerns
    266 Ratings
    Knew the important information about your medical history
    271 Ratings
    The provider showed respect for what you had to say
    271 Ratings
    The provider spent enough time with me
    270 Ratings
    Decorative Caduceus

    CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia

    MTD is defined as the cohort of participants one cohort below the cohort that develop dose-limiting toxicity (DLT) in at least 2 participants.